BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist for Neuroscience Research

Executive Summary: BIIE 0246 is a potent and selective antagonist of the neuropeptide Y Y2 receptor (Y2R), exhibiting IC₅₀ values of 3.3 nM for Y2R inhibition (APExBIO, product page). It blocks presynaptic inhibitory effects mediated by Y2R, supporting studies of feeding, anxiety, and the neuropeptide Y signaling pathway (Fan et al., 2024). BIIE 0246 demonstrates complete suppression of PYY3-36-induced contraction in rat colon and attenuates PYY(3-36)-induced reduction in feeding (internal). The compound is stable, highly soluble in DMSO (67.2 mg/ml), and suitable for central and peripheral nervous system research (APExBIO). Its use advances translational research on the adipose-neural axis and post-prandial satiety mechanisms (internal).

Biological Rationale

The neuropeptide Y (NPY) system regulates critical processes in the central and peripheral nervous systems, including appetite, anxiety, and cardiovascular function (Fan et al., 2024). Y2R is a G-protein-coupled receptor (GPCR) widely expressed in regions such as the hippocampus, hypothalamus, and enteric nervous system. Presynaptic Y2Rs mediate negative feedback by inhibiting NPY release, thereby modulating synaptic transmission and neuronal excitability. Dysregulation of the NPY/Y2R axis has been implicated in metabolic syndrome, obesity, anxiety disorders, and cardiac arrhythmias. Targeted antagonism of Y2R using highly selective compounds like BIIE 0246 allows researchers to dissect the receptor’s specific physiological and pathophysiological roles. Recent translational models highlight the adipose-neural axis—where leptin and NPY interact with Y1 and Y2 receptors—as a driver in cardiometabolic disease (Fan et al., 2024). Thus, Y2R antagonists are essential for experimental validation of NPY pathway hypotheses in basic and applied research.

Mechanism of Action of BIIE 0246

BIIE 0246 is a highly potent and selective antagonist of the neuropeptide Y Y2 receptor. Its affinity for Y2R is characterized by an IC₅₀ of 3.3 nM and Ki values between 8–15 nM for PYY3-36 binding sites (APExBIO, product data). BIIE 0246 competitively blocks Y2R, preventing endogenous NPY and PYY3-36 from engaging the receptor. Mechanistically, this blockade disrupts presynaptic inhibitory feedback, leading to increased neurotransmitter release at affected synapses. In hippocampal slice models, BIIE 0246 suppresses NPY-induced inhibition of primary afterdischarge activity and population excitatory postsynaptic potentials. In peripheral tissues, such as rat colon, BIIE 0246 completely inhibits contractions induced by PYY3-36, confirming functional antagonism in smooth muscle. The compound’s effects are specific to Y2R, with negligible activity at other NPY receptors (Y1, Y4, Y5) at comparable concentrations (internal analysis).

Evidence & Benchmarks

• BIIE 0246 exhibits an IC₅₀ of 3.3 nM and Ki values of 8–15 nM for Y2R in radioligand-binding assays (APExBIO, product page).
• In rat hippocampal slices, BIIE 0246 blocks NPY-induced inhibition of afterdischarge activity, indicating functional antagonism of presynaptic Y2R (internal).
• BIIE 0246 completely inhibits PYY3-36-induced contraction in rat colon, validating peripheral Y2R blockade (APExBIO, product page).
• The compound attenuates PYY(3-36)-induced reduction in feeding in rodent models, linking Y2R to post-prandial satiety (Fan et al., 2024).
• BIIE 0246 shows anxiolytic-like effects in elevated plus-maze assays, supporting its utility in behavioral neuroscience (internal).
• Recent studies implicate NPY/Y2R signaling in the adipose-neural axis, with BIIE 0246 poised to clarify Y2R roles in cardiac arrhythmia models (Fan et al., 2024).

Applications, Limits & Misconceptions

BIIE 0246 is a benchmark tool for dissecting NPY Y2R signaling in both central and peripheral models. Applications include:

• Validation of Y2R’s role in feeding behavior and satiety regulation.
• Assessment of anxiolytic-like effects and stress-response pathways.
• Interrogation of adipose-neural axis contributions to cardiometabolic disease.
• Dissection of presynaptic inhibitory mechanisms in hippocampal or enteric circuits.

This article extends the mechanistic insights described in BIIE 0246: Selective Neuropeptide Y Y2 Receptor Antagonist by integrating the latest human adipose-neural axis findings (Fan et al., 2024), and clarifies how BIIE 0246 can be used to experimentally validate these translational models. For a strategic overview of translational research using Y2R antagonists, see BIIE 0246 and the Adipose-Neural Axis; this article updates that landscape with recent phenotypic benchmarks.

Common Pitfalls or Misconceptions

• BIIE 0246 does not antagonize other NPY receptor subtypes (Y1, Y4, Y5) at recommended concentrations; its selectivity is well-established (APExBIO).
• The compound is not effective for in vivo diagnostic or therapeutic use; it is intended for research only (APExBIO).
• Long-term storage of BIIE 0246 solutions leads to degradation; freshly prepared aliquots are recommended for experimental reproducibility.
• Observed effects outside established NPY/Y2R pathways (e.g., unrelated GPCRs) require independent validation and should not be attributed to BIIE 0246 without control data.
• BIIE 0246’s anxiolytic-like effects are model-dependent and may not generalize across all behavioral paradigms (internal).

Workflow Integration & Parameters

BIIE 0246 is supplied as a white solid (molecular weight: 896.06; chemical formula: C₄₉H₅₇N₁₁O₆). Stock solutions can be prepared at up to 67.2 mg/ml in DMSO or 23.55 mg/ml in ethanol. For optimal solubility and stability, dissolve in DMSO and store at 4°C; long-term storage of solutions is not advised (APExBIO, B6836 kit). In typical in vitro protocols, final concentrations range from 1–100 nM, depending on cell type, tissue, and endpoint. In vivo studies in rodents generally use systemic or ICV doses scaled to the target tissue and pharmacokinetic properties. Y2R expression should be confirmed in the experimental system by molecular or immunohistochemical techniques. Appropriate negative controls (vehicle, non-selective antagonists) are recommended for specificity.

For advanced translational workflows, BIIE 0246 can be integrated with coculture models of adipocytes, neurons, and cardiac cells, as described in recent human arrhythmia research (Fan et al., 2024). This supports mechanistic studies of the adipose-neural axis, leveraging the selectivity and potency of BIIE 0246 to isolate Y2R-specific effects. To explore complementary signaling targets or combinatorial blockade, researchers may consult Rewiring Translational Research—this article clarifies the unique contribution of Y2R antagonism compared to other neuropeptide pathways.

Conclusion & Outlook

BIIE 0246, distributed by APExBIO, is a gold-standard tool for selective inhibition of the neuropeptide Y Y2 receptor in neuroscience and metabolic research. Its high affinity, robust selectivity, and proven biological benchmarks make it essential for dissecting the role of Y2R in feeding, anxiety, and the adipose-neural axis. As translational models of cardiac arrhythmia and metabolic syndrome increasingly implicate NPY/Y2R signaling (Fan et al., 2024), BIIE 0246 will be critical for hypothesis-driven experiments and mechanistic validation. Researchers are encouraged to leverage this compound in conjunction with emerging coculture and behavioral paradigms, using rigorous controls and reporting standards for maximal reproducibility. For ordering and detailed specifications, refer to the APExBIO BIIE 0246 product page.